Werewolf Therapeutics (HOWL) vs Tevogen (TVGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Werewolf Therapeutics (HOWL) has outperformed Tevogen (TVGN) over the past year, losing 51.6% versus a loss of 80.5%. Werewolf Therapeutics is the larger company by market cap ($47.6 million vs $46.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HOWL | TVGN |
|---|---|---|
| Share price | $0.9792 | $7.15 |
| Market cap | $47.59M | $46.56M |
| 1-day change | +7.60% | +1.27% |
| YTD return | +43.53% | -57.34% |
| 1-year return | -51.60% | -80.50% |
| 5-year return | -94.67% | — |
| EPS (TTM) | $-0.73 | $-6.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.85 | $39.00 |
| 52-week low | $0.27 | $3.64 |
| Distance from 52-week high | -47.07% | -81.67% |
| Analyst consensus | none | — |
| Avg. price target upside | +614.87% | — |
| Average volume | 6.80M | 10.03K |
| Shares outstanding | 48.60M | 6.51M |
| Employees | 39 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HOWL has outperformed TVGN by 28.9 percentage points over the past year.
About Werewolf Therapeutics
HOWL stock →Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
About Tevogen
TVGN stock →Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
HOWL vs TVGN FAQ
Which is bigger, Werewolf Therapeutics or Tevogen?
Werewolf Therapeutics (HOWL) is larger, with a market capitalization of $47.59M compared with $46.56M for Tevogen (TVGN).
Which stock has performed better over the past year, HOWL or TVGN?
HOWL returned -51.60% over the past 12 months, compared with -80.50% for TVGN (price return, excluding dividends). Past performance does not predict future results.
Are Werewolf Therapeutics and Tevogen in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Werewolf Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Tevogen.